Takeda pays $35 million for Colo. vaccine developer

05/8/2013 | Denver Post, The

Takeda Pharmaceutical, through Takeda America Holdings, agreed to acquire Inviragen for $35 million in cash plus $215 million in potential milestone fees contingent on the progress of the firm's infectious-disease vaccines. Inviragen is developing vaccines for dengue as well as hand, foot and mouth disease.

View Full Article in:

Denver Post, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC